Bovine Herpesvirus 1

Overview and Taxonomy of Bovine Herpesvirus 1

Bovine herpesvirus 1 (BoHV-1) stands as one of the most economically significant viral pathogens affecting cattle populations worldwide, representing a persistent and recurring threat to both dairy and beef production systems. This virus, a member of the Alphaherpesvirinae subfamily within the Herpesviridae family, is the etiological agent of infectious bovine rhinotracheitis (IBR), a disease complex that manifests as upper respiratory tract infections, conjunctivitis, genital disorders, and reproductive failure, including abortion [1, 2, 5]. The World Organisation for Animal Health (WOAH) classifies BoHV-1 as a pathogen of considerable economic and trade significance, as its presence can impose stringent restrictions on international cattle movement and commerce.

Taxonomic Classification and Virion Structure

BoHV-1 is taxonomically classified within the order Herpesvirales, family Herpesviridae, subfamily Alphaherpesvirinae, and genus Varicellovirus [3, 4]. This classification aligns it with other significant alphaherpesviruses such as herpes simplex virus type 1 (HSV-1) in humans and suid alphaherpesvirus 1 (SuHV-1) in swine, with which it shares fundamental biological properties including a short reproductive cycle, rapid spread in cell culture, and the hallmark ability to establish lifelong latency in sensory neurons [2, 5, 10]. The virion itself is structurally complex, measuring approximately 150–200 nm in diameter, and is composed of four distinct architectural components: an electron-dense core containing the linear double-stranded DNA genome, an icosahedral capsid, an amorphous tegument layer, and a lipid envelope studded with viral glycoproteins [1].

The BoHV-1 genome is a linear double-stranded DNA molecule of approximately 135–138 kilobase pairs, organized into a unique long (UL) and unique short (US) segment, each flanked by inverted repeat sequences [1, 5]. This genomic architecture is characteristic of the Varicellovirus genus and encodes upwards of 70–80 proteins, including essential structural components, enzymes required for viral DNA replication, and numerous regulatory and immunomodulatory factors. Among the most critical gene products are the immediate-early transcriptional regulatory proteins, particularly bovine infected cell protein 0 (bICP0) and bICP4, which orchestrate the cascade of viral gene expression necessary for productive infection [7, 19]. The tegument, a proteinaceous layer located between the capsid and envelope, contains viral proteins such as VP8 and UL41 that are delivered into the host cell immediately upon entry, where they function to shut off host protein synthesis and modulate the cellular environment to favor viral replication [5, 6].

Geographic Distribution and Economic Significance

BoHV-1 infection exhibits a global distribution, and its seroprevalence varies dramatically across different geographic regions and management systems, reflecting the interplay of biosecurity practices, vaccination strategies, and livestock density. Comprehensive serological surveys have demonstrated that BoHV-1 is endemic in many parts of the world. In North-Eastern Mexico, a study reported a seroprevalence of 64.4% in unvaccinated cattle, with herd size and introduction of new animals identified as significant risk factors [9]. Similarly, in the state of Paraná, Brazil, a large-scale cross-sectional study estimated herd-level seroprevalence at 71.3% and animal-level prevalence at 59.0%, with factors such as beef production systems, natural service, and purchase of animals increasing the odds of infection [13]. Within Europe, an Irish national study found that 74.9% of herds (serum pool analysis) and 80% (bulk milk analysis) were seropositive for BoHV-1, despite the fact that vaccine usage was remarkably low at only 1.8% of farmers [15]. Further Irish data indicated that 88% and 80% of dairy herds yielded positive annual bulk milk readings for BVDV and BoHV-1, respectively, while only 5.4% of unvaccinated weanling serum samples were seropositive for BoHV-1, suggesting lower exposure rates in younger stock [12]. In Asia, seroprevalence data from India revealed a 39.2% positivity rate across a large sample set, with notably higher rates in buffaloes (85%) and yaks (71.1%) compared to cattle (38%), highlighting species-specific differences in exposure or susceptibility [17]. A study in the Uttarakhand region of India reported an overall prevalence of 29.03%, with higher rates in unorganized dairy units (31.02%) compared to organized farms (26.51%) [8].

The economic burden imposed by BoHV-1 is staggering, driven by direct losses from clinical disease and indirect losses from trade restrictions and reduced productivity. The virus is the number one infectious agent associated with abortions in cattle and a major contributor to the bovine respiratory disease complex (BRDC), a polymicrobial disorder that costs the US cattle industry in excess of one billion dollars annually [1, 5]. Beyond the acute clinical manifestations, the lifelong latency established in sensory neurons means that infected animals serve as reservoirs for virus transmission throughout their lives, with periodic reactivation events, triggered by stress, transportation, parturition, or corticosteroid administration, leading to renewed virus shedding and transmission to susceptible cohorts [2, 10].

Clinical Manifestations and Pathogenesis

The clinical spectrum of BoHV-1 infection is broad, encompassing respiratory, ocular, genital, and reproductive forms of disease. Respiratory tract infections constitute the predominant clinical manifestation, typically presenting as infectious bovine rhinotracheitis (IBR), characterized by fever, depression, nasal discharge, conjunctivitis, and severe inflammation of the upper respiratory tract mucosa [1, 5]. The virus replicates extensively in the nasal epithelium, turbinates, and trachea, causing extensive cellular destruction and inflammation that compromises the respiratory defense mechanisms. This damage, combined with the virus’s potent immunosuppressive properties, predisposes animals to secondary bacterial infections, particularly with Mannheimia haemolytica, culminating in the severe fibrinonecrotic pneumonia characteristic of BRDC [1, 14]. Gene expression profiling of bovine bronchial epithelial cells co-infected with BoHV-1 and M. haemolytica reveals a significant upregulation of inflammation-associated genes such as CXCL2, IL-6, IL-1α, and IL-8, along with genes involved in vascular function and leukocyte migration, providing a molecular basis for the exacerbated pathology observed during polymicrobial infections [14].

BoHV-1 also causes genital infections, including infectious pustular vulvovaginitis (IPV) in females and balanoposthitis in males, which are transmitted venereally and can lead to temporary infertility and abortion [1, 4]. Reproductive failure is a particularly devastating consequence, as the virus can cross the placenta and infect the developing fetus, resulting in fetal death, mummification, or the birth of weak, non-viable calves [5]. The pathogenesis of abortion involves the virus’s ability to induce apoptosis in infected cells, including lymphocytes, and to evade the host immune response, thereby facilitating systemic spread to the reproductive tract and the gravid uterus [5]. Conjunctivitis and keratoconjunctivitis are also common, especially in younger animals, and may occur with or without concurrent respiratory signs [4, 5].

Latency, Reactivation, and the Stress Connection

Perhaps the most insidious aspect of BoHV-1 biology is its ability to establish lifelong latency in sensory neurons of the trigeminal ganglia following acute infection [2, 10, 18]. During latency, the viral genome persists as an episome within the neuronal nucleus, with viral gene expression restricted primarily to the latency-related (LR) gene locus, which encodes at least two microRNAs and several proteins, including ORF-1 and ORF-2, which are thought to play critical roles in the maintenance of latency and the regulation of reactivation [10, 16]. The LR gene locus is abundantly expressed in latently infected neurons, while the expression of lytic cycle genes is robustly silenced. Intriguingly, a mutant BoHV-1 strain containing three stop codons at the beginning of LR open reading frame 2 fails to reactivate from latency following dexamethasone treatment, underscoring the essential role of LR-encoded proteins in the latency-reactivation cycle [10].

Reactivation from latency is consistently and predictably induced by stress or by the administration of the synthetic corticosteroid dexamethasone, which mimics the physiological stress response [2, 10]. This reactivation event is crucial for virus transmission and represents a major obstacle to eradication. The molecular mechanisms underlying reactivation are complex and involve the convergence of multiple signaling pathways. Increased corticosteroid levels activate the glucocorticoid receptor (GR), a type 1 nuclear hormone receptor, which then directly stimulates viral gene expression [2, 7]. Stress-induced Krüppel-like transcription factors (KLFs), particularly KLF4 and KLF15, are also induced in trigeminal ganglion neurons early during dexamethasone-induced reactivation and form cooperative feed-forward transcription loops with GR to transactivate key viral promoters, including the bICP0 early (E) promoter [2, 7]. The immediate-early transcription unit 1 promoter (IEtu1) drives expression of bICP0 and bICP4, and the separate early promoter for bICP0 is cooperatively transactivated by GR and KLF4, both pioneer transcription factors, in a ligand-independent manner in neuronal cells [7]. This cooperative transactivation of the bICP0 E promoter is critical for stimulating lytic cycle viral gene expression following stressful stimuli, thereby initiating the cascade that leads to production of infectious virus [7]. Beyond GR and KLFs, the β-catenin signaling pathway also plays a role, as BoHV-1 infection transiently increases β-catenin protein levels in non-neuronal cells, and β-catenin-dependent transcription is stimulated by infection [11].

Immune Evasion and Immunopathogenesis

BoHV-1 has evolved a sophisticated arsenal of mechanisms to counteract the host antiviral immune response, which contributes directly to its pathogenesis, the establishment of latency, and the promotion of BRDC. The virus consistently induces transient but profound immunosuppression during acute infection, characterized by the infection and apoptosis of CD4+ T lymphocytes, which cripples the adaptive immune response and creates an immunological window permissive for secondary bacterial infections [1, 5]. The virus encodes several proteins that interfere with key innate immune signaling pathways. The immediate-early protein bICP0 is a multifunctional regulator that inhibits interferon (IFN)-dependent transcription by inducing the degradation of interferon regulatory factor 3 (IRF3) and by interacting with IRF7 to inhibit IFN-β promoter activity [5, 19]. The C3HC4 zinc RING finger domain located near the amino terminus of bICP0 is essential for these functions, and a recombinant virus with a single amino acid change in this finger is severely impaired in growth and fails to reactivate from latency [19]. Additionally, the tegument protein UL41 suppresses the antiviral innate immune response by directly targeting and cleaving the mRNA of STAT1, a critical component of the JAK-STAT signaling pathway, thereby blocking the formation of IFN-stimulated gene factor 3 complexes and repressing the expression of interferon-stimulated genes [6]. The glycoprotein G (gG), UL49.5, and VP8 are among other viral proteins that contribute to immune evasion by interfering with antigen presentation and other antiviral mechanisms [5].

This ability to subvert immune surveillance has profound implications for disease pathogenesis and control. By dampening antiviral responses, BoHV-1 facilitates its own spread within the host, including dissemination to the ovaries and the developing fetus, thereby enhancing reproductive issues such as abortion [5]. Furthermore, the transient immunosuppression disrupts the delicate balance of the respiratory tract microbiome, allowing opportunistic pathogens like Mannheimia haemolytica to proliferate and cause severe bronchopneumonia, a hallmark of BRDC [1, 14]. Understanding these intricate molecular pathways of immune evasion is critical for the rational design of novel vaccines and therapeutics that can effectively block reactivation, reduce virus spread, and mitigate the devastating economic impacts of this globally significant pathogen [2, 5].

Molecular Pathogenesis of Bovine Herpesvirus 1: Latency, Reactivation, and Hormonal Regulation

The Molecular Architecture of Neuronal Latency

The establishment and maintenance of lifelong latency in sensory neurons represents the central, defining feature of BoHV-1 pathogenesis and the primary obstacle to global eradication. Following acute replication in the mucosal epithelium, predominantly of the upper respiratory tract, conjunctiva, or genital tract, the virus gains access to the peripheral nervous system via sensory nerve endings and undergoes retrograde axonal transport to the neuronal cell bodies within the trigeminal ganglia (TG) and, to a lesser extent, the sacral dorsal root ganglia [1, 2]. Within this sanctuary, the viral genome persists as a circular, non-integrated episome. The lytic cycle transcriptional program is almost entirely silenced, with the notable exception of a single, complex locus: the latency-related (LR) gene. This locus is the only region of the BoHV-1 genome that is robustly and consistently transcribed during latency [10]. The LR gene does not encode a single product but rather a family of RNA species produced through alternative splicing, which are processed into at least two known microRNAs and several proteins, including the products of open reading frames (ORF)-1, ORF-2, and RF-C [10, 16]. Compelling evidence from mutant virus studies demonstrates that the products of the LR gene are not merely bystanders of latency but are actively required for the maintenance of this state. Specifically, calves latently infected with a mutant BoHV-1 strain harboring three in-frame stop codons at the N-terminus of LR ORF-2 fail to reactivate from latency following corticosteroid induction, in stark contrast to calves infected with wild-type virus [10]. The ORF-1 protein, which is expressed in productively infected bovine cells and localizes to both the cytoplasm and nucleus, is also detectable in the trigeminal ganglia of latently infected calves, suggesting its expression may be a critical component of the latency maintenance program [16].

Hormonal Regulation and Stress-Induced Reactivation: The Glucocorticoid Receptor Orchestrates a Transcriptional Cascade

The ability of BoHV-1 to reactivate from its latent state is a highly regulated event, and the central trigger for this process in cattle is physiological stress. The stress-induced elevation of endogenous corticosteroids can be reliably mimicked by the administration of the synthetic corticosteroid dexamethasone (DEX), which consistently and predictably induces reactivation in latently infected calves and rabbits [2, 5, 10]. This model has proven invaluable for dissecting the molecular choreography of reactivation. The primary effector is the glucocorticoid receptor (GR), a type I nuclear hormone receptor that, upon ligand binding, translocates to the nucleus where it acts as a pioneer transcription factor. GR directly binds to specific response elements within key viral promoters to initiate gene expression. A landmark finding is that GR does not act alone. It engages in a sophisticated feed-forward transcription loop with Krüppel-like transcription factors (KLFs), particularly KLF4 and KLF15, whose expression is itself induced by stress and DEX [2, 7]. This cooperative transactivation is critical for driving the expression of the viral immediate-early and early genes. The immediate-early transcription unit 1 (IEtu1) promoter, which drives expression of the essential regulatory proteins bICP0 and bICP4, is a key target of the GR/KLF15 complex [7]. Furthermore, the bICP0 gene is also driven by a distinct early (E) promoter. Remarkably, GR and KLF4 cooperatively transactivate this bICP0 E promoter to a significantly greater degree than GR and KLF15, and this activation occurs in a ligand-independent manner [7]. This intricate layering of transcriptional control ensures that the viral lytic cycle is reactivated in a sequential and efficient manner following a stress signal. The consequence of this feed-forward loop is a rapid amplification of viral gene expression, beginning with the key regulatory protein bICP0. The importance of bICP0 cannot be overstated: it is a multifunctional protein containing a C3HC4 zinc RING finger domain essential for its role as a viral transactivator and for the degradation of cellular antiviral factors such as interferon regulatory factor 3 (IRF3) [19]. Mutations in this RING finger render the virus unable to reactivate from latency in cattle, confirming that bICP0 function is a non-negotiable requirement for lytic reactivation [19].

Beyond Glucocorticoids: The Role of the β-Catenin/Wnt Signaling Axis and Other Nuclear Hormone Receptors

While the GR/KLF axis is paramount, the molecular pathogenesis of reactivation is not monocausal. BoHV-1 has evolved to exploit multiple convergent signaling pathways activated by stress. One such pathway is the β-catenin-dependent Wnt signaling cascade. During latency, viral gene products stabilize β-catenin levels within TG neurons, and subsequent productive infection in non-neuronal cells transiently increases β-catenin protein levels, which in turn stimulates β-catenin-dependent transcription [11]. This is not a trivial epiphenomenon; the small molecule inhibitor of β-catenin (iCRT14) significantly reduces BoHV-1 virus titers during productive infection in bovine kidney cells, demonstrating that this signaling pathway is a functional driver of viral replication [11]. The implication is that β-catenin's known ability to promote cell survival and cell cycle progression creates a cellular environment that is highly favorable for the efficient completion of the viral lytic cycle [11].

Furthermore, the virus's capacity to sense and respond to the broader hormonal milieu extends beyond glucocorticoids. The type 1 nuclear hormone receptor family includes receptors for androgens and progesterone. Intriguingly, both the androgen receptor and the progesterone receptor can also drive BoHV-1 gene expression and productive infection, mirroring the action of GR [2]. This is biologically significant, as it provides a direct molecular link between the high progesterone levels characteristic of pregnancy and the increased susceptibility to BoHV-1-induced abortion. The ability of these different steroid hormone receptors to converge on the same feed-forward transcription loops involving KLF4 and KLF15 reveals a powerful evolutionary adaptation: BoHV-1 has essentially "hijacked" a core family of host stress and reproductive signaling pathways to serve as a master switch for its own life cycle [2].

Viral Countermeasures and the Balancing Act of Reactivation: Immune Evasion as a Prerequisite

Reactivation from latency is not simply a matter of turning on viral genes; it requires the virus to simultaneously dismantle the host's antiviral defenses that would otherwise contain the nascent infection. This is a critical point of coordination in the molecular pathogenesis of BoHV-1. The stress signal itself provides a two-pronged advantage. While the corticosteroid surge directly stimulates viral gene expression via GR, it also is a potent physiological immunosuppressant, impairing innate and adaptive immunity [5]. However, BoHV-1 also encodes a sophisticated arsenal of viral proteins dedicated to subverting the remaining immune surveillance. The already discussed bICP0, in addition to its role in transactivation, actively degrades IRF3 and inhibits the transactivation of the IFN-β promoter, thereby crippling the type I interferon response, a cornerstone of antiviral immunity [5, 19]. Another tegument protein, UL41, acts as a host shutoff factor that directly targets the STAT1 transcript for degradation, effectively blocking the JAK-STAT signaling pathway that is essential for establishing an interferon-stimulated gene (ISG) response [6]. This dual assault, direct transcriptional repression of interferon and degradation of its signaling components, ensures that the virus can reactivate and spread to adjacent epithelial cells with reduced risk of being cleared by the host's first-line defenses. The consequence of this transient immunosuppression is profound, as it not only facilitates viral transmission but also opens the door for polymicrobial infections, most notably the establishment of the bovine respiratory disease complex (BRDC), a major cause of economic loss in the cattle industry [1, 5].

The Immediate Consequences of Reactivation: Inflammasomes, Apoptosis, and Co-infection

The culmination of reactivation is the anterograde transport of newly assembled virions back to the periphery, leading to lytic infection of the respiratory or genital epithelia. This phase is characterized not just by viral replication but by significant immunopathology. BoHV-1 productive infection directly stimulates the formation of the inflammasome, a multiprotein complex that activates caspase 1. In bovine kidney cells, infection induces the expression of key inflammasome components, including the DNA sensor IFI16 and NLRP3, leading to a dramatic increase in caspase 1-positive cells [22]. Caspase 1 activation drives the maturation of pro-inflammatory cytokines like IL-1β, which directly contributes to the clinical signs of inflammation and fever observed during acute disease. The infected epithelium is also subject to virus-induced apoptosis. In some cell models, such as mouse neuroblastoma (Neuro-2A) cells, apoptosis occurs concurrently with signs of incomplete autophagy [20]. This interplay is complex; proteasome inhibitors like MG-132 can switch the cellular response from apoptosis towards autophagy, which has been shown to reduce efficient virus release [21]. This suggests that BoHV-1 may actively manipulate cell death pathways to favor its own dissemination, for instance, using apoptosis as a mechanism for non-lytic release of viral progeny while simultaneously blocking the autophagic process that could serve as an antiviral defense [20, 21]. This final lytic stage of the reactivation cycle, therefore, is a highly regulated process of cellular destruction and inflammation that serves to maximize viral shedding and transmission to new hosts. The profound inflammatory response and the virus-induced immunosuppression create the ideal environment for secondary bacterial invaders, particularly Mannheimia haemolytica, to colonize the lower respiratory tract, leading to the severe fibrinopurulent bronchopneumonia that characterizes BRD [1, 14]. The virus thus acts as a key initiator in a pathogenic cascade that is far more damaging than the viral infection alone, a fact that places BoHV-1 at the apex of the major disease complexes facing cattle producers worldwide.

Epidemiology and Global Impact of Bovine Herpesvirus 1

Global Distribution and Seroprevalence Patterns

Bovine herpesvirus 1 (BoHV-1) represents one of the most economically significant viral pathogens affecting cattle populations worldwide, with a truly global distribution that spans every continent where cattle husbandry is practiced [3, 4]. The virus is endemic in most cattle-producing regions, with seroprevalence rates varying dramatically based on geographic location, management practices, vaccination programs, and biosecurity measures. The World Organisation for Animal Health (WOAH) classifies BoHV-1 as a notifiable pathogen in many member countries, reflecting its substantial impact on international trade and animal health [4].

Seroprevalence studies from diverse geographic regions reveal the pervasive nature of this infection. In North America, BoHV-1 is considered ubiquitous, with the virus being identified as the number one infectious agent associated with abortions in cattle and a primary contributor to the bovine respiratory disease complex (BRDC) [5]. The economic burden in the United States alone is staggering, with BoHV-1-induced immunosuppression and its role in initiating polymicrobial respiratory disease costing the US cattle industry more than one billion dollars annually [5]. Seroprevalence data from Mexico's northeastern Tamaulipas region, a critical cattle production area and principal exporter of calves and heifers to the United States, demonstrates a 64.4% seroprevalence in unvaccinated cattle, with significant risk factors including rural district, herd size, and introduction of new animals [9].

South America exhibits similarly high infection rates. A comprehensive cross-sectional study conducted in the state of Paraná, Brazil, involving 14,803 females from 2,018 non-vaccinated herds, revealed an apparent herd-level seroprevalence of 71.3% and animal-level seroprevalence of 59.0% [13]. Multiple logistic regression analysis identified several critical risk factors: beef herds (odds ratio [OR] = 1.58), natural service breeding (OR = 1.48), purchase of animals (OR = 1.90), pasture rental (OR = 2.24), existence of calving pens (OR = 1.56), and records of abortion in the preceding 12 months (OR = 1.45) [13]. These findings underscore the multifactorial nature of BoHV-1 transmission and the importance of management practices in disease perpetuation.

European data reveal a heterogeneous epidemiological landscape. In Ireland, a nationally representative study of 305 dairy herds found that 80% of herds yielded mean annual positive bulk milk readings for BoHV-1, despite only 12% of farmers vaccinating against the virus [12]. A subsequent comprehensive analysis of 1,175 Irish dairy and beef herds confirmed a herd-level seroprevalence of 74.9%, with no significant difference between dairy and beef operations, and a notable association between herd size and seroprevalence [15]. Alarmingly, only 1.8% of Irish farmers used BoHV-1 marker vaccines at the time of that study, indicating a substantial gap between infection pressure and control measures [15].

Asian epidemiological data demonstrate equally concerning patterns. In India, screening of 1,115 serum samples from cattle, bulls, buffalo bulls, and yaks across multiple states revealed an overall seropositivity of 39.2%, with state-level variation ranging from 71.1% in Assam yaks to 68.9% in Madhya Pradesh cattle, while Meghalaya showed no detectable antibodies [17]. A focused study in five districts of Uttarakhand, India, examining 489 serum samples from unvaccinated bovines, found an overall prevalence of 29.03%, with buffaloes exhibiting higher prevalence (38.14%) than cattle (26.78%), and females (30.08%) showing greater seropositivity than males (16.21%) [8]. These data highlight the species and sex predilections that complicate epidemiological understanding and control strategies.

Transmission Dynamics and Risk Factors

The epidemiology of BoHV-1 is fundamentally shaped by its unique biological characteristics, particularly its ability to establish lifelong latency in sensory neurons with periodic reactivation [2, 10]. This latency-reactivation cycle represents the single most important factor in viral persistence and transmission within cattle populations. Following acute infection, BoHV-1 establishes latency primarily in the trigeminal ganglia of the peripheral nervous system, where the latency-related (LR) gene locus is abundantly expressed, encoding at least two microRNAs and several proteins that maintain the latent state [10, 16]. The LR gene contains multiple open reading frames, including ORF-1 and ORF-2, with studies demonstrating that ORF-1 protein expression is detectable in trigeminal ganglia of latently infected calves, suggesting its importance in the latency-reactivation cycle [16].

Reactivation from latency is consistently triggered by physiological and environmental stressors that elevate corticosteroid levels [2, 5]. The synthetic corticosteroid dexamethasone reliably induces reactivation in latently infected calves, making it an invaluable experimental model [2, 10]. The molecular mechanisms underlying stress-induced reactivation are remarkably complex. Glucocorticoids, acting through the glucocorticoid receptor (GR), directly regulate BoHV-1 gene expression through multiple pathways, including β-catenin-dependent Wnt signaling [2, 11]. The stress-induced Krüppel-like transcription factors KLF4 and KLF15 form feed-forward transcription loops with GR, cooperatively transactivating key viral promoters such as the bICP0 early promoter [2, 7]. This intricate regulatory network ensures that stressful conditions, transport, weaning, overcrowding, temperature extremes, parturition, or concurrent disease, can precipitate viral reactivation, leading to virus shedding and transmission to naive animals [2, 5].

Quantitative risk assessment modeling provides critical insights into introduction probabilities at the farm level. A comprehensive study incorporating official animal movement data, biosecurity questionnaires, and expert opinion estimated the median annual probability of BoHV-1 introduction into dairy herds through animal movements at 9%, with farms purchasing cattle from within their region and sharing transport vehicles facing significantly higher risks [24]. The model identified several high-risk practices: purchasing or introducing cattle, rearing replacement heifers offsite, showing cattle at competitions, sharing transport vehicles, and transporting cattle in uncleaned vehicles [24]. These findings emphasize that human-mediated movements constitute the primary mechanism for between-herd transmission.

Direct transmission occurs through respiratory secretions, genital secretions, and aborted fetal tissues [4]. The virus can be shed in nasal secretions for up to 14 days following acute infection, and reactivation events typically result in virus shedding for 4-7 days [4]. Aerosol transmission over short distances is efficient, particularly in confined housing systems. Venereal transmission through infected semen is another significant route, with bulls shedding virus in semen during both acute infection and reactivation episodes [4]. The introduction of latently infected animals into naive herds represents the most common inciting event for outbreaks.

Economic Impact and Production Losses

The economic consequences of BoHV-1 infection are profound and multifaceted, encompassing direct losses from clinical disease, indirect losses from trade restrictions, and the substantial costs of control and eradication programs. The most significant economic impact derives from the virus's role as a primary initiator of the bovine respiratory disease complex (BRDC), a polymicrobial disorder that represents the leading cause of morbidity and mortality in feedlot cattle worldwide [1, 5]. BoHV-1-induced immunosuppression, mediated through infection of lymphocytes and induction of apoptosis in CD4+ T cells, creates a permissive environment for secondary bacterial pathogens, particularly Mannheimia haemolytica [5, 14]. Transcriptomic analysis of bovine bronchial epithelial cells co-infected with BoHV-1 and M. haemolytica reveals dramatic upregulation of inflammatory mediators, including TNF-α, IL-8, IL-1, CXCL2, and CSF2, along with vascular function genes and leukocyte migration factors, explaining the severe pneumonic pathology observed in BRDC [14].

Reproductive losses constitute another major economic burden. BoHV-1 is the leading infectious cause of abortion in cattle, with infection of pregnant cows potentially resulting in fetal death at any stage of gestation [5]. The virus's ability to interfere with antiviral immune responses promotes viral spread to ovaries and the developing fetus, enhancing reproductive pathology [5]. Experimental challenge studies demonstrate that naive pregnant cows exposed to BoHV-1 experience abortion rates exceeding 70%, while even vaccinated animals may experience fetal infection and loss if immunity wanes [29]. The economic impact extends beyond immediate fetal loss to include reduced conception rates, extended calving intervals, increased veterinary costs, and premature culling of affected animals.

Trade restrictions represent a substantial economic consideration for BoHV-1-endemic regions. Many countries, particularly those that have achieved eradication or are implementing control programs, impose strict import requirements on cattle and bovine products from endemic areas [4]. The European Union's classification of BoHV-1 as a List B disease has driven several member states to implement compulsory eradication programs, creating trade barriers for regions with high prevalence. The cost of testing, quarantine, and certification for export animals adds significant overhead to cattle operations in endemic areas.

Age, Sex, and Species-Related Epidemiological Patterns

Epidemiological studies consistently reveal important demographic variations in BoHV-1 seroprevalence. Age is a well-established risk factor, with seroprevalence increasing with age as cumulative exposure opportunities accumulate [4]. Young animals may be partially protected by maternal antibodies during the first months of life, but this protection wanes, leaving weaned calves and yearlings particularly susceptible to primary infection. The Irish study examining weanlings with a mean age of 291 days found 5.4% seropositivity for BoHV-1, compared to 80% herd-level seroprevalence in adult dairy herds, illustrating the age-dependent acquisition of infection [12].

Sex-based differences in seroprevalence have been documented, with females consistently showing higher seropositivity than males. In the Uttarakhand study, 30.08% of females were seropositive compared to 16.21% of males [8]. This disparity likely reflects management practices, with females being retained longer in herds and thus having greater cumulative exposure, as well as potential physiological factors related to pregnancy and lactation that may influence susceptibility or reactivation risk.

Species differences are also noteworthy. Buffaloes appear to be more susceptible or more frequently exposed than cattle in some regions. The Indian studies found 38.14% seropositivity in buffaloes versus 26.78% in cattle [8], and 85% seropositivity in buffalo bulls compared to 38.6% in cattle bulls [17]. Yaks showed remarkably high seroprevalence at 71.1% in Assam [17], suggesting that BoHV-1 circulates efficiently in these populations and may represent a reservoir for transmission to cattle.

Seasonal and Management-Related Epidemiological Patterns

Seasonal patterns in BoHV-1 transmission and disease manifestation are well documented. The Irish bulk milk study identified a significant seasonal trend in BoHV-1 antibody levels, with more herds categorized as positive in the latter half of the year [12]. This seasonality likely reflects management practices such as housing cattle during winter months, which increases contact rates and aerosol transmission, as well as the stress of weaning and transport that typically occurs in autumn. In temperate regions, outbreaks of infectious bovine rhinotracheitis (IBR) are most common during fall and winter when cattle are confined [4].

Management system profoundly influences BoHV-1 epidemiology. Dairy herds, with their intensive management, frequent introductions of replacement animals, and high stocking densities, typically exhibit different epidemiological patterns than beef herds. The Brazilian study found that beef herds had 1.58 times higher odds of BoHV-1 seropositivity compared to dairy herds [13], potentially reflecting differences in biosecurity practices, vaccination rates, and animal movement patterns. Unorganized dairy units in India showed higher seroprevalence (31.02%) compared to organized farms (26.51%), suggesting that structured management with better biosecurity can reduce infection pressure [8].

Herd size consistently emerges as a significant risk factor, with larger herds showing higher seroprevalence [9, 13, 15]. This relationship reflects the increased probability of virus introduction and maintenance in larger populations, where the continuous influx of susceptible animals through births and purchases sustains transmission. The Irish study found a significant association between herd size quartiles and seroprevalence quartiles, confirming this dose-response relationship [15].

Diagnostic and Surveillance Considerations

Accurate epidemiological assessment of BoHV-1 relies on robust diagnostic tools. Serological surveillance using enzyme-linked immunosorbent assays (ELISA) remains the mainstay for herd-level prevalence studies, with both indirect and competitive ELISA formats available [8, 9, 13, 15]. The use of bulk milk ELISA for dairy herds provides a cost-effective surveillance method, with studies demonstrating 95.5% agreement in herd classification between bulk milk and serum pools [15]. The development of glycoprotein E (gE) deletion marker vaccines has enabled differentiation of infected from vaccinated animals (DIVA), a critical tool for eradication programs [31]. The BoHV-1ΔgE recombinant vaccine, constructed by replacing the full gE coding region with a GFP marker, replicates efficiently in vitro and induces virus-neutralizing antibodies in calves while allowing serological differentiation from wild-type infection using anti-gE antibody ELISA [31].

Molecular diagnostic methods, particularly real-time PCR, have revolutionized BoHV-1 detection. A one-step multiplex real-time RT-PCR assay targeting the highly conserved glycoprotein B gene enables simultaneous detection of BoHV-1 along with bovine respiratory syncytial virus and bovine parainfluenza virus 3, the three primary viral agents of BRD [33]. This assay demonstrates 97% sensitivity in detecting 10² copies of viral nucleic acid and has proven superior to traditional virus isolation and immunofluorescence testing for clinical samples [33]. Such molecular tools are essential for rapid outbreak confirmation, latency detection, and surveillance programs.

Global Control and Eradication Efforts

The global impact of BoHV-1 has prompted diverse control strategies, ranging from voluntary vaccination programs to compulsory eradication campaigns. Several European countries, including Switzerland, Austria, Finland, Sweden, Norway, and Denmark, have successfully eradicated BoHV-1 through comprehensive stamping-out programs combined with movement restrictions and biosecurity measures [4]. These programs typically involve serological surveillance of all cattle herds, removal of seropositive animals, and strict controls on animal movements. The success of these programs demonstrates that eradication is achievable, albeit at substantial financial cost and requiring strong political will and industry cooperation.

In regions where eradication is not immediately feasible, vaccination remains the primary control tool. Modified live virus (MLV) vaccines and inactivated vaccines are most frequently used globally, while attenuated and inactivated marker vaccines are preferentially used in Europe to support DIVA strategies [1]. The efficacy of vaccination in preventing reproductive losses was demonstrated in a study comparing annual revaccination with MLV vaccine versus combination MLV/killed vaccine, where both regimens provided substantial protection against fetal infection and abortion following challenge with BoHV-1 and BVDV [29]. However, current vaccines have significant limitations: they limit disease severity and virus shedding but do not prevent infection or establishment of latency, and MLV vaccines carry the risk of causing disease in immunocompromised animals or pregnant cattle [1, 28].

Novel vaccine approaches under investigation include vectored vaccines using Newcastle disease virus expressing glycoprotein D, which induces mucosal and systemic antibody responses and provides partial protection against challenge [34]. DNA vaccines incorporating bovine neutrophil beta-defensin 3 as a molecular adjuvant have shown promise in enhancing cell-mediated immune responses, particularly CD8+ IFN-γ+ cytotoxic T lymphocytes [32]. Recombinant BoHV-1 with deletions in virulence genes, such as the bICP0 zinc RING finger mutant, demonstrate severely impaired growth and inability to reactivate from latency, representing potential next-generation vaccine candidates [19].

The development of antiviral therapies represents an alternative approach to reducing BoHV-1 impact. Several compounds have shown in vitro efficacy, including silver nanoparticles that protect cell cultures from BoHV-1 infection at non-toxic concentrations [27], ellagitannins such as castalagin and vescalagin with selectivity indices of 45 and 42.5 respectively against BoHV-1 [26], and the fungal metabolite 3-O-methylfunicone which significantly reduces virus titer and inhibits expression of the major regulatory protein bICP0 [23]. Ivermectin, an approved antiparasitic drug, inhibits BoHV-1 DNA polymerase nuclear import and reduces viral replication in a dose-dependent manner without affecting virus attachment or entry [25]. DNA aptamers targeting BoHV-1 glycoproteins have demonstrated high-affinity binding and efficient inhibition of viral entry, representing novel diagnostic and therapeutic tools [30].

Clinical Manifestations and Disease Syndromes of Bovine Herpesvirus 1

Infection with bovine herpesvirus 1 (BoHV-1) is a globally pervasive and economically devastating condition affecting cattle populations, recognized by the World Organisation for Animal Health (WOAH) as a notifiable pathogen due to its profound impact on trade and productivity. The clinical expression of BoHV-1 is remarkably pleiotropic, ranging from subclinical seroconversion to severe, life-threatening systemic disease. The virus’s capacity to establish lifelong latency in sensory ganglia, coupled with its potent immunosuppressive properties, ensures that its clinical footprint is not merely a function of acute viral replication but also a consequence of secondary polymicrobial invasions and recrudescent episodes. The disease syndromes are broadly categorized by their anatomical predilection, with the respiratory, ocular, reproductive, and, less commonly, neurological systems serving as primary targets. The severity and specific manifestation of these syndromes are dictated by a complex interplay of viral strain virulence, host immune status, environmental stressors, and the presence of concurrent pathogens.

Respiratory Tract Manifestations: Infectious Bovine Rhinotracheitis and the Bovine Respiratory Disease Complex

The most clinically significant and frequently encountered manifestation of BoHV-1 infection is infectious bovine rhinotracheitis (IBR), an acute, febrile disease of the upper respiratory tract. This syndrome is the primary reason BoHV-1 is considered a cornerstone pathogen in the bovine respiratory disease complex (BRDC) [1, 5]. Following an incubation period of roughly 2 to 6 days, the clinical onset is characterized by a sudden spike in body temperature, often exceeding 40°C, accompanied by profound depression, anorexia, and a marked drop in milk production in lactating animals. The hallmark clinical signs stem from severe inflammation of the nasal passages, trachea, and larynx. Affected cattle develop a copious, serous nasal discharge that rapidly progresses to a mucopurulent or fibrinous exudate, often leading to crusting and excoriation around the nares. The nasal mucosa becomes intensely hyperemic, earning the disease its colloquial name “red nose.” Dyspnea, tachypnea, and a harsh, dry cough are frequently observed due to tracheitis and laryngeal edema. The pathological damage to the respiratory epithelium, characterized by necrosis and erosion of the ciliated cells, strips the airway of its primary mucociliary clearance mechanism [2].

Crucially, the clinical significance of IBR extends far beyond the initial viral insult. One of the most devastating aspects of this syndrome is the profound and transient immunosuppression induced by BoHV-1 [1, 5]. The virus infects and induces apoptosis in CD4+ T lymphocytes, critically impairing cell-mediated immunity and the orchestration of adaptive responses [5]. This immunological vacuum creates a permissive environment for opportunistic bacterial pathogens, most notably Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni, to colonize the lower respiratory tract. This viral-bacterial synergy is the central driver of the BRDC, a polymicrobial disease that represents the single greatest cause of morbidity, mortality, and economic loss to the cattle industry, with annual losses in the United States alone exceeding one billion dollars [5]. Transcriptomic analyses of bovine bronchial epithelial cells co-infected with BoHV-1 and M. haemolytica reveal a synergistic upregulation of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and other chemokines, which potentiate the severe fibrinous pleuropneumonia characteristic of terminal BRDC [14]. Consequently, while death from uncomplicated IBR is rare, mortality in the context of secondary bacterial pneumonia is substantial.

Ocular Manifestations: Infectious Bovine Keratoconjunctivitis

While often overshadowed by respiratory disease, ocular involvement is a frequent component of acute BoHV-1 infection. The virus directly infects the conjunctival epithelium, leading to a clinical presentation that can be indistinguishable from Moraxella bovis infection, the primary cause of infectious bovine keratoconjunctivitis (pinkeye) [1, 5]. The ocular syndrome typically includes profuse serous lacrimation, conjunctival hyperemia, photophobia, and blepharospasm. In severe cases, corneal edema and the development of superficial ulcers may occur, although panophthalmitis is rare in uncomplicated BoHV-1 infections. This manifestation is particularly problematic in young calves and feedlot cattle, where stress and crowding facilitate rapid transmission. The presence of ocular discharge serves as a potent source of environmental contamination and fomite spread, amplifying outbreak dynamics within a herd.

Reproductive Manifestations: Abortion, Vulvovaginitis, and Balanoposthitis

BoHV-1 is a leading infectious cause of reproductive failure in cattle, a fact that underpins its classification as a major threat to herd fertility and genetic improvement [5]. The reproductive syndromes can be categorized into venereal and non-venereal disease. The venereal form, infectious pustular vulvovaginitis (IPV) in females and infectious balanoposthitis (IBP) in males, results from coital transmission. In cows and heifers, IPV is characterized by inflammation of the vulvar and vaginal mucosa, with the development of small, raised pustules. These pustules often rupture, leaving shallow, painful erosions. The clinical signs include frequent urination, tail swishing, and a mucopurulent vaginal discharge, which can lead to temporary infertility due to pain-induced mating refusal or impaired sperm transport. In bulls, IBP presents with similar pustular lesions on the penis and prepuce, which can cause pain and reluctance to serve, temporarily compromising breeding soundness [3, 4].

The most economically ruinous reproductive manifestation, however, is abortion. Abortion is not a consequence of venereal infection of the dam during pregnancy but typically results from a primary respiratory or systemic infection that leads to viremia. The virus, adept at circumventing host antiviral defenses, disseminates hematogenously and crosses the placental barrier to infect the developing fetus [5]. The risk of abortion is highest when a naive, pregnant animal is exposed to the virus and develops a systemic infection. Fetal death is attributed to a combination of direct viral cytopathology, severe vasculitis of the placental cotyledons, and the induction of a robust fetal inflammatory response, including inflammasome formation [22]. Abortions can occur anywhere from several days to several weeks post-infection, with the majority occurring between 4 and 8 months of gestation. The abortion rate in a susceptible, naive herd can be alarmingly high, often reaching 25% to 60% [5]. Fetal infection earlier in gestation can also result in the birth of persistently infected or weak, non-viable calves, although this is less common than in bovine viral diarrhea virus (BVDV) infections. Vaccination strategies, particularly with modified-live vaccines (MLV) administered pre-breeding, are critically effective at preventing the fetal infection that leads to abortion [29].

Neurological and Enteric Manifestations

While less common than the respiratory and reproductive forms, BoHV-1 infection can manifest as a non-suppurative meningoencephalitis, predominantly in young calves. This neurological form is referred to as “IBR encephalitis” and is characterized by ataxia, muscle tremors, blindness, head pressing, convulsions, and ultimately, recumbency and death. The pathogenesis involves viral entry into the central nervous system (CNS) via the trigeminal nerve or olfactory tract following severe respiratory infection. Studies using mouse neuroblastoma (Neuro-2A) cells have demonstrated that BoHV-1 can exert direct neurotoxicity through a combination of apoptosis and necrosis, with evidence of incomplete autophagy that may favor viral persistence in neuronal cells [20]. Although infrequent in adult cattle, this encephalitic form carries a mortality rate approaching 100% in affected calves. Additionally, mild enteric signs, including diarrhea, have been reported in some outbreaks, though BoHV-1 is not considered a primary enteric pathogen and such signs are typically overshadowed by the respiratory component [4].

The Syndromic Importance of the Latency-Reactivation Cycle

A fundamental aspect of the clinical epidemiology of BoHV-1 is the lifelong, latent infection established in the sensory neurons of the trigeminal ganglia following the resolution of acute disease [2, 10]. This latency is not a state of quiescence but a dynamic equilibrium. The latently infected animal remains a permanent reservoir for the virus. Stressful stimuli, including weaning, transportation, overcrowding, parturition, inclement weather, and concurrent disease, trigger a neuroendocrine response characterized by elevated levels of corticosteroids [2]. These glucocorticoids, particularly cortisol, directly activate the glucocorticoid receptor (GR) in neurons, which cooperates with Krüppel-like transcription factors (KLF4, KLF15) to transactivate the viral bICP0 early promoter, initiating the lytic cycle [7]. This reactivation event leads to the de novo production of infectious virus, which is then shed in nasal, ocular, and genital secretions, often in the absence of overt clinical signs in the carrier animal [2, 10]. This phenomenon of “silent shedding” is a profound challenge to eradication programs, as subclinically reactivating animals can introduce the virus to naive populations with devastating consequences, particularly in pregnant females where reactivation can precipitate abortion storms. The ability of stress to drive this latency-reactivation cycle is the single most critical factor underlying the endemic persistence of BoHV-1 in cattle populations worldwide [2, 10].

Diagnostic Approaches for Bovine Herpesvirus 1 Infection

The accurate and timely diagnosis of Bovine Herpesvirus 1 (BoHV-1) infection is a cornerstone of effective disease control, surveillance, and eradication programs. Given the virus's ability to establish lifelong latency in sensory neurons and reactivate under stress, diagnostic strategies must be multifaceted, capable of detecting not only acute clinical disease but also subclinical infections and latent carriers. The economic impact of BoHV-1, as a primary agent of infectious bovine rhinotracheitis (IBR) and a major contributor to the bovine respiratory disease complex (BRDC), necessitates robust diagnostic protocols that align with international standards set by the World Organisation for Animal Health (WOAH). The diagnostic landscape for BoHV-1 has evolved significantly, moving from traditional virus isolation and serological profiling to highly sensitive molecular techniques and the development of marker vaccines that enable differentiation of infected from vaccinated animals (DIVA). A comprehensive diagnostic approach integrates clinical observation, sample selection, laboratory testing, and epidemiological context, all of which are critical for interpreting results in a population where seroprevalence can range from 29% in parts of India to over 70% in regions of Brazil and Ireland [8, 13, 15].

Traditional and Virological Methods

Historically, the gold standard for BoHV-1 diagnosis has been virus isolation (VI) from clinical specimens. This method involves inoculating susceptible cell lines, such as Madin-Darby Bovine Kidney (MDBK) cells or bovine turbinate cells, with samples from nasal swabs, ocular swabs, genital swabs, or tissues from aborted fetuses [28, 33]. The characteristic cytopathic effect (CPE), typically observed within 24-72 hours, is confirmed by immunofluorescence or immunoperoxidase staining using specific antibodies. While VI is highly specific and provides a live virus isolate for further characterization, its sensitivity is limited by the presence of infectious virus, which is often low during latent infection or late-stage disease. Furthermore, the process is time-consuming and requires stringent sample handling to preserve viral viability, as BoHV-1 is enveloped and labile. The virus's entry pathway, which involves a low-pH-dependent endosomal route, underscores the importance of maintaining sample integrity to ensure successful isolation in cell culture [28]. Despite these limitations, VI remains a critical tool for confirming outbreaks and for research purposes, such as the construction of recombinant viruses like the gE-deleted marker vaccine strain, which was shown to replicate with similar kinetics to wild-type virus in MDBK cells [31].

Serological Diagnostics: Detecting Exposure and Immune Status

Serological assays are indispensable for herd-level surveillance, determining seroprevalence, and certifying animals for trade. The most widely used serological tests are enzyme-linked immunosorbent assays (ELISAs) and virus neutralization tests (VNTs). ELISAs, particularly indirect ELISAs, are favored for their high throughput, objectivity, and ability to detect antibodies against specific viral proteins. Studies across diverse geographical regions have utilized ELISAs to estimate seroprevalence, revealing rates of 64.4% in unvaccinated cattle in Mexico, 74.9% at the herd level in Ireland, and 59.0% at the animal level in Paraná, Brazil [9, 13, 15]. The avidin-biotin ELISA system has been employed effectively in Indian studies, detecting a 29.03% overall seroprevalence in Uttarakhand, with higher rates in buffaloes (38.14%) compared to cattle (26.78%) [8]. These data highlight the endemic nature of BoHV-1 and the critical role of serology in mapping its distribution.

The VNT remains the reference standard for serological testing, particularly for international trade. It measures functional neutralizing antibodies and is highly specific. However, it is more labor-intensive, requires cell culture facilities, and takes several days to complete. A key limitation of conventional serology is its inability to distinguish between antibodies induced by natural infection and those from vaccination. This challenge has been addressed through the development of DIVA vaccines, most notably those lacking the glycoprotein E (gE) gene. Companion ELISAs that detect antibodies against gE allow for the differentiation of infected animals (which will be gE antibody-positive) from those vaccinated with a gE-deleted marker vaccine (which will be gE antibody-negative) [31]. This strategy is crucial for eradication programs, particularly in Europe, where marker vaccines are preferentially used [1]. The use of bulk milk ELISA for BoHV-1 antibodies in dairy herds offers a cost-effective, non-invasive method for herd-level monitoring, with studies showing 95.5% agreement in herd classification between bulk milk and serum pools [15].

Molecular Diagnostics: The Power of Nucleic Acid Detection

The advent of polymerase chain reaction (PCR) has revolutionized BoHV-1 diagnostics, offering unparalleled sensitivity, specificity, and speed. Real-time PCR (qPCR) assays, particularly those targeting conserved genes like the glycoprotein B (gB) gene, are now the primary method for detecting viral DNA in clinical samples [33]. These assays can detect as few as 10-100 copies of viral DNA, making them far more sensitive than virus isolation, especially in samples with low viral loads or compromised virus integrity. The development of multiplex real-time reverse transcriptase PCR (mRT-qPCR) assays has been a significant advancement, allowing for the simultaneous detection of BoHV-1 alongside other major BRD pathogens, such as bovine respiratory syncytial virus (BRSV) and bovine parainfluenza virus type 3 (BPI3) [33]. This multiplexing capability is invaluable for diagnosing the polymicrobial nature of BRDC, where BoHV-1-induced immunosuppression often precipitates secondary bacterial infections [1, 5].

Molecular methods are also essential for understanding viral pathogenesis at the cellular level. For instance, qPCR has been used to quantify the inhibitory effects of novel antiviral compounds, such as the DNA aptamer IBRV-A4, which was shown to block viral entry and significantly reduce viral replication in MDBK cells [30]. Similarly, studies on the fungal metabolite 3-O-methylfunicone (OMF) used qPCR to demonstrate a significant reduction in viral titer and inhibition of the major regulatory protein bICP0 [23]. The ability to detect and quantify viral mRNA transcripts, such as those from the latency-related (LR) gene, provides insights into the latent state. While the LR gene is abundantly expressed in latently infected sensory neurons, the detection of lytic cycle transcripts (e.g., bICP0, gC) is indicative of active viral replication or reactivation [2, 10]. This molecular distinction is critical for diagnosing reactivation events, which are often subclinical but epidemiologically significant.

The Critical Challenge: Diagnosing Latency and Reactivation

The most formidable diagnostic challenge posed by BoHV-1 is its ability to establish lifelong latency in sensory neurons of the trigeminal ganglia, from which it can periodically reactivate [2, 10, 18]. Standard diagnostic tests on nasal or ocular swabs will be negative during true latency, as no infectious virus is shed. The only definitive method to confirm latency is the detection of viral DNA or LR gene transcripts in ganglionic tissue, which is impractical in live animals. Explant culture of trigeminal ganglia, a technique used for decades, can reactivate latent virus in vitro, but this is a research tool, not a routine diagnostic [18].

Reactivation from latency is a stochastic event driven by stress, immunosuppression, or corticosteroid administration [2, 7]. The synthetic corticosteroid dexamethasone is a potent and consistent inducer of reactivation in experimentally infected calves, providing a model to study the molecular triggers [2, 10]. During reactivation, the virus rapidly switches from a quiescent state to productive replication, driven by a complex interplay of cellular transcription factors. Stress-induced glucocorticoid receptor (GR) activation, along with Krüppel-like transcription factors (KLF4 and KLF15), cooperatively transactivate the bICP0 early promoter, a key event in initiating the lytic cycle [7]. This feed-forward loop, involving β-catenin signaling and the androgen and progesterone receptors, highlights the profound influence of host physiology on viral recrudescence [2, 11]. Consequently, a negative PCR result from a nasal swab does not rule out BoHV-1 infection; it merely indicates the absence of active viral shedding at that moment. This has profound implications for biosecurity, as latently infected animals can be introduced into naive herds and shed virus during periods of stress, such as transport or parturition [24]. The development of novel therapeutics aimed at blocking reactivation, such as those targeting the GR-KLF4 feed-forward loop, represents a future avenue for controlling transmission from latent carriers [2].

Emerging and Specialized Diagnostic Technologies

Beyond established methods, several emerging technologies are expanding the diagnostic toolkit for BoHV-1. DNA aptamers, such as IBRV-A4, generated through systematic evolution of ligands by exponential enrichment (SELEX), offer a novel approach for both diagnosis and therapy. This aptamer binds to BoHV-1 with high affinity (Kd of 3.519 nM) and can neutralize viral entry, making it a potential tool for point-of-care diagnostics or as a therapeutic agent [30]. The use of silver nanoparticles (Ag-NPs) has also been explored for their antiviral properties, showing a protective effect against BoHV-1 infection in cell culture at non-toxic concentrations [27]. While not yet a diagnostic tool, this research underscores the potential for nanotechnology in future detection and treatment platforms.

Furthermore, the study of host-pathogen interactions at the molecular level has identified potential biomarkers of infection. For example, the cellular microRNA bta-miR-2361 is significantly downregulated during BoHV-1 infection, and its overexpression inhibits viral replication by targeting the EGR1 gene [35]. Similarly, the tegument protein UL41 directly targets and cleaves STAT1 mRNA to suppress the innate immune response [6]. Detecting such host responses, or the presence of viral proteins like bICP0, which is a master regulator of the lytic cycle and an inhibitor of interferon signaling, could provide indirect evidence of active infection [19]. The inflammasome formation and caspase-1 activation observed during productive infection also represent potential targets for diagnostic assays [22]. These advanced molecular insights are paving the way for more nuanced diagnostic approaches that can differentiate between active replication, latency, and reactivation, moving beyond simple detection of viral nucleic acid or antibodies.

Vaccination Strategies and Antiviral Therapeutics for Bovine Herpesvirus 1

The development and implementation of effective countermeasures against Bovine Herpesvirus 1 (BoHV-1) is a complex and urgent challenge, given the virus's global prevalence, its role as a primary causative agent of the bovine respiratory disease complex (BRDC), and its profound economic impact on the cattle industry [1, 2, 4]. Control strategies are bifurcated into two principal, often complementary, approaches: prophylactic vaccination to prevent infection and limit disease, and antiviral therapeutics to treat active infection or, more ideally, to block the critical processes of reactivation from latency. The interplay between these strategies is governed by the unique biology of BoHV-1, particularly its ability to establish lifelong latency in sensory neurons and reactivate under stress, mechanisms that must be understood for any intervention to be truly successful [1, 2, 10].

Conventional Vaccination Approaches: Modified-Live and Inactivated Vaccines

The cornerstone of BoHV-1 control for decades has been vaccination, with modified-live virus (MLV) and inactivated (killed) vaccines representing the most widely used modalities globally [1]. MLV vaccines, which contain live but attenuated forms of the virus, are generally favored for their ability to induce a robust, balanced immune response encompassing both humoral (antibody-mediated) and cell-mediated immunity. This is critical for controlling an intracellular pathogen like BoHV-1, where cytotoxic T lymphocytes (CTLs) are essential for clearing infected cells [1, 29]. Inactivated vaccines, while safer in terms of reversion to virulence, typically stimulate a weaker, predominantly humoral response and often require adjuvants and booster doses to achieve protective immunity [1, 29].

A landmark study by Walz et al. (2017) directly compared the efficacy of a multivalent MLV vaccine with a combination vaccine (CV) containing temperature-sensitive MLV BoHV-1 and killed BVDV in a rigorous reproductive challenge model. Heifers primed with two pre-breeding doses of MLV and then annually revaccinated with either the MLV or CV vaccine were exposed to BoHV-1 challenge during gestation. The results were striking: abortions occurred in 13% of MLV-vaccinated cows and only 4.5% of CV-vaccinated cows, compared to a catastrophic 73% in non-vaccinated controls. Furthermore, fetal infection with BoHV-1 was prevented entirely in the CV group and was seen in only 17% of the MLV group, versus 100% of controls [29]. This study provides powerful evidence that prime-boost strategies, potentially using different vaccine platforms, can confer superior protection against the most economically damaging consequence of BoHV-1 infection, reproductive failure, even when faced with heterologous field virus challenge. Despite their efficacy, a major and well-documented limitation of conventional MLV BoHV-1 vaccines is their inability to prevent the establishment of latency following infection and, critically, their own potential to reactivate from latency, contributing to the cycle of transmission [1, 34]. This inherent drawback has spurred the development of next-generation vaccines.

The Advent of Marker Vaccines and DIVA Strategies

To overcome the limitations of conventional vaccines and facilitate eradication programs, the concept of marker vaccines, coupled with a "Differentiating Infected from Vaccinated Animals" (DIVA) strategy, has been a significant advancement, particularly in Europe. These vaccines are genetically engineered to be attenuated while lacking a specific non-essential viral glycoprotein, most commonly glycoprotein E (gE) [1, 31]. The fundamental principle is that a vaccinated animal will mount an immune response to all viral proteins except the deleted one. In contrast, a naturally infected animal will produce antibodies against the entire viral proteome, including gE. Serological tests (ELISAs) that specifically detect antibodies against the deleted marker protein (e.g., anti-gE ELISAs) can then unequivocally distinguish a vaccinated animal from a naturally infected one.

Weiss et al. (2015) constructed a gE-deleted BoHV-1 recombinant from a Brazilian genital isolate (BoHV-1ΔgE) by replacing the gE coding region with a GFP marker gene. This recombinant replicated with similar kinetics to wild-type virus in vitro, indicating the deletion of gE did not impair its ability to grow to high titers for vaccine production. When inoculated into calves, BoHV-1ΔgE induced virus-neutralizing antibodies, demonstrating its immunogenicity. Crucially, the serological response induced by this recombinant could be clearly differentiated from that of wild-type BoHV-1 infection using a commercial anti-gE ELISA kit [31]. This proof-of-concept study underscores the viability of gE-deleted marker vaccines as core tools for control and eventual eradication, allowing for the monitoring of virus circulation even in vaccinated herds. The regulatory success of such DIVA strategies depends on the parallel availability and rigorous use of companion discriminatory diagnostic tests, a framework recognized by the World Organisation for Animal Health (WOAH) for the control of several transboundary animal diseases.

Novel Vaccine Platforms: Vectored and DNA Vaccines

The pursuit of safer, more efficacious vaccines that avoid the safety concerns of MLV vaccines (latency, reactivation) while mimicking their immunogenicity has led to the exploration of novel platforms, including viral-vectored and DNA vaccines. Viral-vectored vaccines use a harmless virus (the vector) to deliver and express one or more key BoHV-1 immunogens, often the major neutralizing antigen, glycoprotein D (gD) [1, 34]. A study by Khattar et al. (2010) investigated the use of recombinant Newcastle disease virus (rNDV) vectors to express BoHV-1 gD. A single intranasal and intratracheal inoculation of calves with rNDV expressing native gD (rLaSota/gDFL) elicited robust mucosal and systemic antibody responses. Following a virulent BoHV-1 challenge, these calves exhibited lower viral titers, earlier viral clearance, and reduced clinical disease compared to controls. This study highlighted the potential of NDV as a mucosal vaccine vector, which is particularly attractive for a respiratory pathogen like BoHV-1 [34].

DNA vaccines represent another promising avenue. They consist of plasmid DNA encoding an antigen, which is taken up by host cells, leading to endogenous antigen expression, processing, and presentation via major histocompatibility complex (MHC) class I and II pathways, thereby stimulating both humoral and cellular immunity. Mackenzie-Dyck et al. (2014) explored a DNA vaccine strategy encoding a fusion of truncated gD (tgD) with the bovine neutrophil beta-defensin 3 (BNBD3), a molecule with immunomodulatory properties. In cattle, this fusion vaccine increased the number of IFN-γ-secreting cells, specifically CD8+ IFN-γ+ cytotoxic T lymphocytes, following BoHV-1 challenge. While it did not enhance protection over a tgD-alone vaccine in terms of clinical outcome, it demonstrated that DNA vaccines could be manipulated to modulate the type of immune response generated, a powerful tool for fine-tuning vaccine efficacy [32]. These vectored and DNA platforms offer critical advantages: they cannot cause disease or establish latency in the host, they are stable, and they offer a clear differentiation from natural infection without the need for complex marker deletions [1].

Antiviral Therapeutics: Targeting the Viral Life Cycle and Host Factors

While vaccination remains the primary control strategy, a critical gap exists in the therapeutic arsenal, particularly for treating active infection, managing outbreaks in valuable stock, and, most importantly, for developing drugs that can prevent or interrupt the latent-reactivation cycle [2, 23, 25]. Current options are limited, but research into novel antivirals is robust, targeting various stages of the BoHV-1 life cycle.

Inhibitors of Viral Entry and Nuclear Transport: A detailed understanding of the entry pathway provides logical targets. BoHV-1 has been shown to enter host cells via a low-pH-dependent endocytosis pathway, a process that is critical for viral fusion and release into the cytoplasm [28]. This mechanism presents a druggable target. Another crucial early step is the nuclear import of the viral genome for replication. The viral DNA polymerase holoenzyme comprises a catalytic subunit (pUL30) and a processivity factor (pUL42). Raza et al. (2020) demonstrated that pUL42, which contains a classical nuclear localization signal (cNLS), is responsible for shuttling the pUL30-pUL42 complex into the nucleus. They discovered that the FDA-approved antiparasitic drug Ivermectin, a known inhibitor of importin α/β-mediated nuclear transport, could significantly reduce pUL42 nuclear import and, consequently, BoHV-1 replication in a dose-dependent manner, without affecting viral attachment or entry [25]. This repurposing of an existing drug offers a promising and cost-effective avenue for antiviral development.

Natural Products and Host-Modulating Compounds: A significant body of research has focused on identifying novel compounds from natural sources that inhibit BoHV-1. Fiorito et al. (2022) showed that the fungal metabolite 3-O-Methylfunicone (OMF) from Talaromyces pinophilus exhibited potent antiviral activity, reducing viral titers and the expression of the key viral regulatory protein bICP0. This effect was correlated with a significant upregulation of the aryl hydrocarbon receptor (AhR), suggesting a novel mechanism of action via host signaling pathways [23]. Similarly, extracts from Thymus capitata were shown to inhibit BoHV-1 by interfering with the early stages of viral adsorption [37]. Ellagitannins like castalagin and vescalagin, derived from plants, have also demonstrated significant in vitro activity against BoHV-1, with selectivity indices comparable to or approaching that of acyclovir, a gold-standard anti-herpes drug for human herpes simplex virus [26]. Silver nanoparticles (Ag-NPs) represent another class of nanomaterials with direct antiviral properties. El-Mohamady et al. (2018) found that non-toxic concentrations of Ag-NPs could protect cell cultures from BoHV-1 infection when added prior to viral infection, likely by blocking viral entry [27].

Inhibitors of the proteasome, such as MG-132, and inhibitors of signaling pathways have also been explored. MG-132 was shown to reduce BoHV-1-induced apoptosis and virus release while stimulating an antiviral autophagic response, significantly limiting viral replication [21]. Given the virus's reliance on host signaling, targeting the phospholipase C (PLC) pathway with inhibitors like U73122 also dramatically reduced BoHV-1 replication in vitro [36]. Furthermore, the β-catenin signaling pathway has been identified as a crucial host factor for productive infection; its inhibition by the small molecule iCRT14 significantly reduced viral yields [11].

Aptamers and Gene-Silencing Approaches: Aptamers, which are short, single-stranded DNA or RNA molecules that fold into unique 3D structures, can bind to viral targets with high affinity and specificity. Xu et al. (2017) generated DNA aptamers targeting the BoHV-1 virion. One aptamer, IBRV-A4, exhibited nanomolar affinity for the virus and potently neutralized infection in vitro by blocking viral entry when added at the time of infection, highlighting its potential as both a diagnostic and therapeutic tool [30].

At the host-pathogen interface, cellular microRNAs (miRNAs) are increasingly recognized as critical regulators. A study by Hou et al. (2019) identified that a host miRNA, bta-miR-2361, is significantly downregulated during BoHV-1 infection. Overexpression of this miRNA inhibited virus replication, while its inhibition enhanced it. The mechanism was elegantly dissected: bta-miR-2361 directly targets the mRNA of the host transcription factor EGR1, which in turn promotes the expression of the viral UL46 gene. Therefore, restoring or overexpressing bta-miR-2361 can suppress a proviral host factor, offering a novel "host-directed" antiviral strategy [35]. These diverse approaches, targeting everything from the virus itself to the cellular machinery it hijacks, represent the next frontier in the fight against this pervasive pathogen.

References

[1] Krishnagopal A, Hurk SVDLd. The biology and development of vaccines for bovine herpesvirus 1.. The Veterinary Journal. 2024. DOI: https://doi.org/10.1016/j.tvjl.2024.106152

[2] Ostler JB, Jones C. The Bovine Herpesvirus 1 Latency-Reactivation Cycle, a Chronic Problem in the Cattle Industry. Viruses. 2023. DOI: https://doi.org/10.3390/v15020552

[3] LtdTM P. bovine herpesvirus 1. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.91729

[4] . bovine herpesvirus 1 infections. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.79283

[5] Jones C. Bovine Herpesvirus 1 Counteracts Immune Responses and Immune-Surveillance to Enhance Pathogenesis and Virus Transmission. Frontiers in Immunology. 2019. DOI: https://doi.org/10.3389/fimmu.2019.01008

[6] Ma W, Wang H, He H. Bovine herpesvirus 1 tegument protein UL41 suppresses antiviral innate immune response via directly targeting STAT1.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2019.108494

[7] El-Mayet FS, Sawant L, Thunuguntla P, Zhao J, Jones C. Two Pioneer Transcription Factors, Krüppel-Like Transcription Factor 4 and Glucocorticoid Receptor, Cooperatively Transactivate the Bovine Herpesvirus 1 ICP0 Early Promoter and Stimulate Productive Infection. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.01670-19

[8] Thakur V, Kumar M, Rathish R. Seroprevalence of bovine herpesvirus-1 antibodies in bovines in five districts of Uttarakhand. Veterinary World. 2017. DOI: https://doi.org/10.14202/vetworld.2017.140-143

[9] Segura-Correa J, Zapata-Campos CC, Jasso-Obregón JO, Martínez-Burnes J, López-Zavala R. Seroprevalence and risk factors associated with bovine herpesvirus 1 and bovine viral diarrhea virus in North-Eastern Mexico. Open Veterinary Journal. 2016. DOI: https://doi.org/10.4314/ovj.v6i2.12

[10] Jones C. Latency of Bovine Herpesvirus 1 (BoHV-1) in Sensory Neurons. . 2016. DOI: https://doi.org/10.5772/63750

[11] Zhu L, Thunuguntla P, Liu Y, Hancock M, Jones C. The β-catenin signaling pathway stimulates bovine herpesvirus 1 productive infection.. Virology. 2016. DOI: https://doi.org/10.1016/j.virol.2016.10.014

[12] Sayers R, Byrne N, O’Doherty E, Arkins S. Prevalence of exposure to bovine viral diarrhoea virus (BVDV) and bovine herpesvirus-1 (BoHV-1) in Irish dairy herds.. Research in Veterinary Science. 2015. DOI: https://doi.org/10.1016/j.rvsc.2015.02.011

[13] Dias JA, Alfieri A, Ferreira-Neto JS, Gonçalves V, Müller EE. Seroprevalence and risk factors of bovine herpesvirus 1 infection in cattle herds in the state of Paraná, Brazil.. Transboundary and Emerging Diseases. 2013. DOI: https://doi.org/10.1111/j.1865-1682.2012.01316.x

[14] N’jai AU, Rivera J, Atapattu D, Owusu-Ofori K, Czuprynski C. Gene expression profiling of bovine bronchial epithelial cells exposed in vitro to bovine herpesvirus 1 and Mannheimia haemolytica. Veterinary Immunology and Immunopathology. 2013. DOI: https://doi.org/10.1016/j.vetimm.2013.06.012

[15] Cowley DB, Clegg T, Doherty M, More S. Aspects of bovine herpesvirus-1 infection in dairy and beef herds in the Republic of Ireland. Acta Veterinaria Scandinavica. 2011. DOI: https://doi.org/10.1186/1751-0147-53-40

[16] Meyer F, Pérez S, Jiang Y, Zhou Y, Henderson G, Jones C. Identification of a novel protein encoded by the latency-related gene of bovine herpesvirus 1. Journal of Neurovirology. 2011. DOI: https://doi.org/10.1080/13550280701620754

[17] Nandi S, Kumar M, Yadav V, Chander V. Serological evidences of bovine herpesvirus-1 infection in bovines of organized farms in India.. Transboundary and Emerging Diseases. 2011. DOI: https://doi.org/10.1111/j.1865-1682.2010.01185.x

[18] Ej H, Bc E. Isolation of bovine herpesvirus-1 from trigeminal ganglia of clinically normal cattle.. American Journal of Veterinary Research. 1980. DOI: https://doi.org/10.2460/ajvr.1980.41.08.1212

[19] Jones C. Regulation of Innate Immune Responses by Bovine Herpesvirus 1 and Infected Cell Protein 0 (bICP0). Viruses. 2009. DOI: https://doi.org/10.3390/v1020255

[20] Fiorito F, Nocera F, Cantiello A, Iovane V, Lambiase S, Piccolo M, et al.. Bovine herpesvirus-1 infection in mouse neuroblastoma (Neuro-2A) cells.. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108762

[21] Fiorito F, Iovane V, Cantiello A, Marullo A, Martino LD, Iovane G. MG-132 reduces virus release in Bovine herpesvirus-1 infection. Scientific Reports. 2017. DOI: https://doi.org/10.1038/s41598-017-13717-1

[22] Wang J, Alexander J, Wiebe MS, Jones C. Bovine herpesvirus 1 productive infection stimulates inflammasome formation and caspase 1 activity.. Virus Research. 2014. DOI: https://doi.org/10.1016/j.virusres.2014.03.006

[23] Fiorito F, Cerracchio C, Salvatore M, Serra F, Pucciarelli A, Amoroso M, et al.. Antiviral Property of the Fungal Metabolite 3-O-Methylfunicone in Bovine Herpesvirus 1 Infection. Microorganisms. 2022. DOI: https://doi.org/10.3390/microorganisms10010188

[24] Benavides B, Casal J, Diéguez J, Yus E, Moya S, Armengol R, et al.. Development of a quantitative risk assessment of bovine viral diarrhea virus and bovine herpesvirus-1 introduction in dairy cattle herds to improve biosecurity.. Journal of Dairy Science. 2020. DOI: https://doi.org/10.3168/jds.2019-17827

[25] Raza S, Shahin F, Zhai W, Li H, Alvisi G, Yang K, et al.. Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes With Viral Replication. Microorganisms. 2020. DOI: https://doi.org/10.3390/microorganisms8030409

[26] Vilhelmova-Ilieva N, Sirakov I, Jacquet R, Quideau S, Galabov A. Antiviral activities of ellagitannins against bovine herpesvirus-1, suid alphaherpesvirus-1 and caprine herpesvirus-1. Journal of Veterinary Medicine and Animal Health. 2020. DOI: https://doi.org/10.5897/JVMAH2020.0857

[27] El-Mohamady R, Ghattas T, Zawrah M, El-Hafeiz YA. Inhibitory effect of silver nanoparticles on bovine herpesvirus-1. International Journal of Veterinary Science and Medicine. 2018. DOI: https://doi.org/10.1016/j.ijvsm.2018.09.002

[28] Pastenkos G, Lee BH, Pritchard S, Nicola A. Bovine Herpesvirus 1 Entry by a Low-pH Endosomal Pathway. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.00839-18

[29] Walz P, Givens M, Rodning S, Riddell K, Brodersen BW, Scruggs D, et al.. Evaluation of reproductive protection against bovine viral diarrhea virus and bovine herpesvirus-1 afforded by annual revaccination with modified-live viral or combination modified-live/killed viral vaccines after primary vaccination with modified-live viral vaccine.. Vaccine. 2017. DOI: https://doi.org/10.1016/j.vaccine.2017.01.006

[30] Xu J, Zhang X, Zhou S, Shen J, Yang D, Wu J, et al.. A DNA aptamer efficiently inhibits the infectivity of Bovine herpesvirus 1 by blocking viral entry. Scientific Reports. 2017. DOI: https://doi.org/10.1038/s41598-017-10070-1

[31] Weiss M, Brum MCS, Anziliero D, Weiblen R, Flores EF. A glycoprotein E gene-deleted bovine herpesvirus 1 as a candidate vaccine strain. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2015. DOI: https://doi.org/10.1590/1414-431X20154243

[32] Mackenzie-Dyck S, Kovacs-Nolan J, Snider M, Babiuk L, Hurk SvDLd. Inclusion of the Bovine Neutrophil Beta-Defensin 3 with Glycoprotein D of Bovine Herpesvirus 1 in a DNA Vaccine Modulates Immune Responses of Mice and Cattle. Clinical and Vaccine Immunology. 2014. DOI: https://doi.org/10.1128/CVI.00696-13

[33] Thonur L, Maley M, Gilray J, Crook TC, Laming E, Turnbull D, et al.. One-step multiplex real time RT-PCR for the detection of bovine respiratory syncytial virus, bovine herpesvirus 1 and bovine parainfluenza virus 3. BMC Veterinary Research. 2012. DOI: https://doi.org/10.1186/1746-6148-8-37

[34] Khattar S, Collins P, Samal S. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine. 2010. DOI: https://doi.org/10.1016/j.vaccine.2010.02.051

[35] Hou P, Zhao M, He W, He H, Wang H. Cellular microRNA bta-miR-2361 inhibits bovine herpesvirus 1 replication by directly targeting EGR1 gene.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/J.VETMIC.2019.05.004

[36] Zhu L, Yuan C, Ding X, Jones C, Zhu G. The role of phospholipase C signaling in bovine herpesvirus 1 infection. Veterinary Research. 2017. DOI: https://doi.org/10.1186/s13567-017-0450-5

[37] Boubaker–Elandalousi R, Mekni-Toujani M, Kaabi B, Larbi I, Diouani M, Gharbi M, et al.. Non-cytotoxic Thymus capitata extracts prevent Bovine herpesvirus-1 infection in cell cultures. BMC Veterinary Research. 2014. DOI: https://doi.org/10.1186/s12917-014-0231-6